Register for our free email digests:
Pennsylvania State University
Latest From PharmAbcine Inc.
PharmAbcine is counting on the success of its lead anticancer antibody tanibirumab following promising early Phase II results, and the South Korean bioventure is planning to raise new funds as it looks to progress this and other pipeline projects.
Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.
Shares of Green Cross LabCell and ST Pharm jumped on their debut following their successful initial public offerings earlier this month. Numerous South Korean biotechs are seeking IPOs this year amid the government's ongoing drive to nurture the biopharma sector and the stock exchange's efforts to ease listing regulations to help fund raising by promising small firms including bioventures.
Following an initial clinical study in South Korea, PharmAbcine is progressing with Phase IIa plans in Australia for its anticancer antibody tanibirumab. The South Korean biotech expects to benefit from the country's ‘outstanding’ clinical trial system and is aiming to initially launch the drug in Australia through a fast-track approval system without a Phase III program.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.